This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Alert me on articles by topic

Catherine Passaretti, MD; Amita Gupta, MD, MHS

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with great interest the article by Hurwitz et al¹ on the impact of selenium supplementation in patients infected with human immunodeficiency virus type 1 (HIV-1). Studies examining the association between micronutrients and HIV, particularly prospective studies, have been limited to date.² Hurwitz et al¹ evaluated the association between selenium supplementation and HIV-1 viral load in a randomized, double-blind, placebo-controlled trial in 262 HIV-infected adults. Human immunodeficiency virus type 1 viral load and CD4 cell count were checked at baseline and at 9 months. Selenium plasma levels and medication adherence were monitored monthly. Based on their results, the authors concluded that daily selenium supplementation can be used as "a simple, inexpensive, and safe adjunct therapy in HIV spectrum disease."^1(p153) Using the CONSORT (Consolidated Standards of Reporting Trials) guidelines for publication of randomized controlled trials³ as well as our assessment of data presented, . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Suppression of Human Immunodeficiency Virus Type 1 Viral Load With Selenium Supplementation: A Randomized Controlled Trial
Barry E. Hurwitz, Johanna R. Klaus, Maria M. Llabre, Alex Gonzalez, Peter J. Lawrence, Kevin J. Maher, Jeffrey M. Greeson, Marianna K. Baum, Gail Shor-Posner, Jay S. Skyler, and Neil Schneiderman
Arch Intern Med. 2007;167(2):148-154.
ABSTRACT | FULL TEXT